Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS | $0.1 | $0.2 | $0.2 | $0.2 | $0.3 | $0.3 | $0.4 | $0.6 | $1.3 | $0.8 | $0.9 | $1.0 | $1.1 | $1.2 | $0.6 | $0.6 | $1.4 | $1.7 | $1.7 | $1.4 |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Novo Nordisk A/S's last 12-month EPS is $3.1, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Novo Nordisk A/S's EPS growth was (24.3%). The average annual EPS growth rates for Novo Nordisk A/S have been 2.3% over the past three years, 4.7% over the past five years.
Over the last year, Novo Nordisk A/S's EPS growth was (24.3%), which is lower than industry growth of (0.2%). It indicates that Novo Nordisk A/S's EPS growth is Bad.